PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9915269-2 1999 EPO resistance is usually attributed to iron or vitamin deficiency, hyperparathyroidism, aluminum toxicity, or inflammation. Aluminum 89-97 erythropoietin Homo sapiens 0-3 15777837-0 2005 The distinct erythropoietin functions that promote cell survival and proliferation are affected by aluminum exposure through mechanisms involving erythropoietin receptor. Aluminum 99-107 erythropoietin Homo sapiens 13-27 15777837-2 2005 Previous results related to the action of aluminum (Al) on erythropoiesis let us suggest that the metal affects Epo interaction with its target cells. Aluminum 42-50 erythropoietin Homo sapiens 112-115 15777837-2 2005 Previous results related to the action of aluminum (Al) on erythropoiesis let us suggest that the metal affects Epo interaction with its target cells. Aluminum 52-54 erythropoietin Homo sapiens 112-115 15777837-4 2005 In the Epo-independent K562 cells, Al inhibited Epo antiapoptotic action and triggered a simultaneous decrease in protein and mRNA EpoR levels. Aluminum 35-37 erythropoietin Homo sapiens 7-10 15777837-4 2005 In the Epo-independent K562 cells, Al inhibited Epo antiapoptotic action and triggered a simultaneous decrease in protein and mRNA EpoR levels. Aluminum 35-37 erythropoietin Homo sapiens 48-51 15777837-5 2005 On the other hand, proliferation of the strongly Epo-dependent UT-7 cells was enhanced by long-term Al treatment, in agreement with the upregulation of EpoR expression during Epo starvation. Aluminum 100-102 erythropoietin Homo sapiens 49-52 15829127-6 2005 The patient was on long-term aludrox therapy 3 g/day, and showed relative resistance to the exogenous hormone erythropoietin, resulting in a refractory anaemia and suggesting aluminium toxicity. Aluminum 175-184 erythropoietin Homo sapiens 110-124 12091599-16 2002 Erythropoietin replacement therapy can correct the anaemia in almost all iron replete patients providing enough hormone is given, functional iron deficiency is avoided, aluminium levels and parathyroid toxicities are controlled and that no de novo haematological condition that affects erythropoiesis or red blood cell survival develops. Aluminum 169-178 erythropoietin Homo sapiens 0-14 11590253-7 2001 Inadequate dialysis can also negatively impact on rh-Epo therapy, and aluminium overload interferes with iron metabolism and reduces the efficacy of rh-Epo. Aluminum 70-79 erythropoietin Homo sapiens 152-155 9159297-1 1997 The treatment efficacy of erythropoietin (EPO) in end-stage renal disease (ESRD) can be limited by deficiencies of iron, folate, or vitamin B12, by hyperparathyroidism, or by aluminum intoxication. Aluminum 175-183 erythropoietin Homo sapiens 26-40 9481432-1 1998 The present study was designed to investigate the impact of aluminum toxicity on the response to recombinant human erythropoietin (rHuEPO) therapy in hemodialysis patients, when iron deficiency has been corrected or excluded. Aluminum 60-68 erythropoietin Homo sapiens 115-129 9263684-5 1997 A provocative hypothesis attempts to link the widespread use of erythropoietin to the emergence of adynamic bone disease-lacking excessive aluminium accumulation. Aluminum 139-148 erythropoietin Homo sapiens 64-78 9689168-0 1998 Effect of serum parathyroid hormone and aluminum levels on the response to erythropoietin in uremia. Aluminum 40-48 erythropoietin Homo sapiens 75-89 9159297-1 1997 The treatment efficacy of erythropoietin (EPO) in end-stage renal disease (ESRD) can be limited by deficiencies of iron, folate, or vitamin B12, by hyperparathyroidism, or by aluminum intoxication. Aluminum 175-183 erythropoietin Homo sapiens 42-45 9156931-6 1996 The results of performed analysis indicate that aluminium is able to inhibit erythropoiesis induced by erythropoietin. Aluminum 48-57 erythropoietin Homo sapiens 103-117 7731142-1 1995 Twenty-three hemodialysis patients exposed to an accidental aluminum overload, showed increased erythropoietin requirements and decreased erythrocyte mean corpuscular volume (MCV). Aluminum 60-68 erythropoietin Homo sapiens 96-110 8506193-0 1993 Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy. Aluminum 54-63 erythropoietin Homo sapiens 32-46 8080342-3 1994 This article discusses how a multidisciplinary renal team can use continuous quality improvement principles to manage a suboptimal response to Epoetin alfa therapy caused by aluminum toxicity. Aluminum 174-182 erythropoietin Homo sapiens 143-150 8289992-1 1993 We examined the relationship between recombinant human erythropoietin (rHuEPO) therapy and serum levels of the trace elements aluminum, silicon, zinc, nickel, and manganese in 55 patients undergoing chronic hemodialysis (HD) in whom rHuEPO (for 12 weeks) was effective in reducing anemia, and in 55 patients undergoing HD without rHuEPO treatment. Aluminum 126-134 erythropoietin Homo sapiens 55-69 8506193-3 1993 Seven out of eight patients without aluminium toxicity responded to r-Hu-EPO therapy. Aluminum 36-45 erythropoietin Homo sapiens 73-76 8506193-7 1993 We therefore confirm r-Hu-EPO resistance owing to aluminium overload and report its successful and safe reversal with low dose DFO therapy. Aluminum 50-59 erythropoietin Homo sapiens 26-29 1328942-0 1992 Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis. Aluminum 0-9 erythropoietin Homo sapiens 53-67 2003757-1 1991 Aluminum overload can have a detrimental effect on erythropoiesis which, in turn, can blunt the effectiveness of Epoetin alfa. Aluminum 0-8 erythropoietin Homo sapiens 113-120 1865507-15 1991 Investigation of influencing factors on response to EPO suggests that 1) TIW group had a better response than BIW group 2) Response was better in patients with more adequate iron status and less severe Al burden. Aluminum 202-204 erythropoietin Homo sapiens 52-55 1865507-18 1991 Dosing regimen, iron status, and serum Al will influence the response to EPO. Aluminum 39-41 erythropoietin Homo sapiens 73-76 1775251-0 1991 Aluminium content of water for injection used with recombinant human erythropoietin. Aluminum 0-9 erythropoietin Homo sapiens 69-83 1870750-0 1991 The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Aluminum 12-21 erythropoietin Homo sapiens 49-63 1775251-6 1991 Ampoules of a second brand of erythropoietin, supplied already in solution, contained from 506 to 837 micrograms/l aluminium (median 682 micrograms/l). Aluminum 115-124 erythropoietin Homo sapiens 30-44 1967718-4 1990 4 patients, who showed only a partial response to erythropoietin, had significantly higher serum aluminium concentrations than the 7 who responded fully (225 [44] vs 55 [23] micrograms/l); erythrocyte protoporphyrin concentrations in partial responders were also much higher than in responders (973 [120] vs 388 [29] nmol/l). Aluminum 97-106 erythropoietin Homo sapiens 50-64 2239943-0 1990 The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment. Aluminum 12-20 erythropoietin Homo sapiens 80-94 2239943-2 1990 Aluminum can blunt the effect of erythropoietin, in part by interfering with iron bioavailability. Aluminum 0-8 erythropoietin Homo sapiens 33-47 2239943-4 1990 A patient is described who developed hematological evidence of aluminum excess after being treated with erythropoietin. Aluminum 63-71 erythropoietin Homo sapiens 104-118 1967718-5 1990 Aluminium intoxication may cause resistance to erythropoietin by interference with haem synthesis, with accumulation of protoporphyrin. Aluminum 0-9 erythropoietin Homo sapiens 47-61 2331725-0 1990 [Does aluminum affect the effectiveness of human recombinant erythropoietin in the treatment of anemia in dialyzed patients?]. Aluminum 6-14 erythropoietin Homo sapiens 61-75 2091687-0 1990 Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism. Aluminum 65-73 erythropoietin Homo sapiens 33-47 2093544-0 1990 Aluminium interference in the treatment with recombinant human erythropoietin. Aluminum 0-9 erythropoietin Homo sapiens 63-77 2113221-0 1990 Aluminium intoxication in the rat induces partial resistance to the effect of recombinant human erythropoietin. Aluminum 0-9 erythropoietin Homo sapiens 96-110 2122321-0 1990 Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. Aluminum 0-9 erythropoietin Homo sapiens 89-103 2809506-6 1989 Thus, aluminium may inhibit EPO responsiveness. Aluminum 6-15 erythropoietin Homo sapiens 28-31 22174104-0 2012 Oxidative stress due to aluminum exposure induces eryptosis which is prevented by erythropoietin. Aluminum 24-32 erythropoietin Homo sapiens 82-96 2684530-0 1989 Effect of aluminum overload on the bone marrow response to recombinant human erythropoietin. Aluminum 10-18 erythropoietin Homo sapiens 77-91 23343454-0 2013 Aluminum in erythropoietin formulations: lyophilized versus liquid forms. Aluminum 0-8 erythropoietin Homo sapiens 12-26 23343454-1 2013 BACKGROUND: Erythropoietin (EPO) formulations may comprise aluminum (Al) as a contaminant. Aluminum 59-67 erythropoietin Homo sapiens 12-26 23343454-1 2013 BACKGROUND: Erythropoietin (EPO) formulations may comprise aluminum (Al) as a contaminant. Aluminum 59-67 erythropoietin Homo sapiens 28-31 23343454-1 2013 BACKGROUND: Erythropoietin (EPO) formulations may comprise aluminum (Al) as a contaminant. Aluminum 69-71 erythropoietin Homo sapiens 12-26 23343454-1 2013 BACKGROUND: Erythropoietin (EPO) formulations may comprise aluminum (Al) as a contaminant. Aluminum 69-71 erythropoietin Homo sapiens 28-31 23343454-3 2013 Since EPO formulations are stored in container-closure systems made of glass and rubber, and both contain Al, formulation ingredients may enable its leaching into the solution during shelf-life. Aluminum 106-108 erythropoietin Homo sapiens 6-9 23343454-7 2013 RESULTS: Glass and rubber are sources of Al for EPO formulations. Aluminum 41-43 erythropoietin Homo sapiens 48-51 23343454-14 2013 CONCLUSION: The difference in the Al measured in liquid forms of EPO and in lyophilized powders suggests that the latter would be the best pharmaceutical form for CKD patients. Aluminum 34-36 erythropoietin Homo sapiens 65-68 22174104-8 2012 Interestingly, erythrocytes were also protected from the prooxidative action of Al by the presence of erythropoietin (EPO). Aluminum 80-82 erythropoietin Homo sapiens 102-116 22174104-8 2012 Interestingly, erythrocytes were also protected from the prooxidative action of Al by the presence of erythropoietin (EPO). Aluminum 80-82 erythropoietin Homo sapiens 118-121 22174104-11 2012 Irrespective of the antioxidant mechanism, this property of EPO, shown in this model of Al exposure, let us suggest potential benefits by EPO treatment of patients with anemia associated to altered redox environment. Aluminum 88-90 erythropoietin Homo sapiens 60-63 22174104-11 2012 Irrespective of the antioxidant mechanism, this property of EPO, shown in this model of Al exposure, let us suggest potential benefits by EPO treatment of patients with anemia associated to altered redox environment. Aluminum 88-90 erythropoietin Homo sapiens 138-141 21983256-0 2011 Evidence for aluminum-binding erythropoietin by size-exclusion chromatography coupled to electrothermal absorption atomic spectrometry. Aluminum 13-21 erythropoietin Homo sapiens 30-44 21983256-2 2011 EPO formulations usually have elevated rates of contamination due to aluminum (Al), which is toxic to both types of patients. Aluminum 69-77 erythropoietin Homo sapiens 0-3 21983256-2 2011 EPO formulations usually have elevated rates of contamination due to aluminum (Al), which is toxic to both types of patients. Aluminum 79-81 erythropoietin Homo sapiens 0-3 21983256-3 2011 Size-exclusion chromatography (SEC) coupled with graphite furnace atomic absorption spectrometry (GF AAS) was employed to separate proteins and to quantify the amount of aluminum present in the elution volume corresponding to EPO and, therefore, to evaluate possible binding. Aluminum 170-178 erythropoietin Homo sapiens 226-229 21983256-6 2011 EPO and HSA samples were incubated with Al for 4h at 4 C and 37 C as well as for 16 h at 4 C and 37 C. Afterwards, they were injected into the chromatographic system. Aluminum 40-42 erythropoietin Homo sapiens 0-3 21983256-8 2011 The results showed that Al was present in the eluent volume corresponding to the EPO peak but not in the HSA peak in the chromatograms. Aluminum 24-26 erythropoietin Homo sapiens 81-84 21983256-9 2011 Temperature strengthened the interaction because the Al present in the EPO fraction was 3 times higher at 37 C compared to 4 C. Thirty-eight percent of the Al present in a 2.4 mug/mL EPO standard solution, and approximately 50% of the Al in formulation samples containing approximately 11 mug/mL EPO and either citrate or phosphate, were non-ultrafiltrable, which suggests that EPO is an effective Al acceptor in vitro. Aluminum 53-55 erythropoietin Homo sapiens 71-74 22371781-9 2010 Both serum aluminium and lead levels positively correlated with the EPO dose taken by the patients (r = 0.77, p = 0.0001 and r = 0.67, p = 0.0001 respectively). Aluminum 11-20 erythropoietin Homo sapiens 68-71